New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:37 EDTNWBONorthwest Biotherapeutics slides after presentation at cancer conference
Northwest Biotherapeutics (NWBO), a development-stage company focused on immunotherapy products that generate and enhance immune system responses to treat cancer, is trading down sharply after the company presented information about its cancer vaccine DC-Vax. The company's disclosures about the brain cancer study had issues, according to a report by Adam Feuerstein of The Street. WHAT'S NOTABLE: Yesterday, Northwest Biotherapeutics disclosed information about its cancer vaccine DC-Vax and its ongoing phase III brain cancer study during a presentation at the New York Academy of Medicine. Feuerstein's report contended that the information was "amazingly negative" and that CEO Linda Powers "spun the bad news in the opposite direction." The biotech reporter added that Powers would not give specific details about patient enrollment in the study. PRICE ACTION: Northwest Biotherapeutics is trading down 62c, or 7.97%, to $7.16 in morning trading. Reference Link
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
06:09 EDTNWBOStocks with implied volatility movement; NWBO ZIOP
Subscribe for More Information
February 25, 2015
10:12 EDTNWBOHigh option volume stocks
High option volume stocks: WBAI HDS ICON NWBO RGR GFI RKT TJX RSG LC
February 19, 2015
12:57 EDTNWBONW Bio Phase III clinical trial of DCVax-L approved to proceed in Canada
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use